By Kamal Choudhury and Mariam Sunny Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental personalized ...

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

Long-term follow-up data from a phase 2b trial of Moderna and MSD's mRNA-based vaccine against melanoma, intismeran autogene ...

A new comprehensive review from researchers at the Icahn School of Medicine at Mount Sinai details how decades of cancer vaccine research are converging into a new era of more precise, personalized, ...

The only man in his immediate family to be without a cancer diagnosis, one Lynch syndrome patient made the trip to ...

A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.

Among patients with advanced melanoma, long-term data have shown that a personalized mRNA cancer vaccine, when combined with ...

Moderna and Merck’s cancer vaccine reduced the risk of relapse or death for melanoma patients, five-year data from a Phase 2b ...

In patients with high-risk melanoma, the personalized cancer vaccine intismeran autogene and Keytruda reduced the risk of ...

January is Cervical Cancer Awareness Month. Here is how we can take early precautions to prevent this- ...

Wall Street is hopeful that a pipeline of cancer drugs can drive earnings growth as the respiratory vaccine business flounders.

Jan 20 () - Moderna ​and Merck ‌said on ‌Tuesday their experimental vaccine for ⁠a ‌serious type of ‍skin cancer, used in ...